诱导治疗结束时主要患者报告结局的缓解可预测克罗恩病的临床与内镜缓解
该研究为对251例克罗恩病临床试验数据的事后分析,评估生物制剂诱导治疗后主要患者报告结局(PRO)缓解与1年临床缓解(CDAI<150)和/或内镜缓解(SES-CD<3)的关系。结果显示,诱导后主要PRO缓解者达到联合内镜与临床缓解的比值比更高(aOR 1.94,95%CI 1.01-3.74,P=0.047),且与诱导后内镜应答联合时aOR达6.89(95%CI 1.65-28.72,P=0.008);而临床应答或PRO2应答未预测这些结局。结论认为诱导后主要PRO缓解与1年结局强相关,但需进一步验证。
要点
- 诱导后主要PRO缓解与1年联合内镜和临床缓解相关(aOR 1.94,P=0.047)。
- 主要PRO缓解联合诱导后内镜应答与1年联合缓解强相关(aOR 6.89,P=0.008)。
- 临床应答或PRO2应答未预测1年临床与内镜缓解。
核心结论
- 诱导治疗后主要PRO缓解(而非临床应答或PRO2应答)与1年內镜和临床缓解强相关,可能对1年结局有提示意义,但需进一步验证。
研究设计与样本
- 对251例克罗恩病临床试验数据的事后分析,评估生物制剂诱导治疗后主要PRO缓解或临床应答与1年临床缓解(CDAI<150)和/或内镜缓解(SES-CD<3)的关系,采用多变量逻辑回归模型校正混杂因素。
主要发现
- 诱导后主要PRO缓解者达到联合内镜和临床缓解的比值比高于未缓解者(aOR 1.94,95%CI 1.01-3.74,P=0.047)。
- 主要PRO缓解联合诱导后内镜应答(SES-CD较基线降低≥50%)与1年联合内镜和临床缓解的比值比更高(aOR 6.89,95%CI 1.65-28.72,P=0.008)。
- 诱导后临床应答(CDAI降低≥100)或PRO2应答(排便频率降低≥30%和/或腹痛评分降低≥30%且均不差于基线)未预测1年联合内镜和临床缓解。
- 诱导后主要PRO缓解、临床应答或PRO2应答与1年内镜缓解均无显著差异。
关键数值与推荐
- 主要PRO定义为基线时升高最严重的PRO。
- 临床应答定义为CDAI降低≥100。
- PRO2应答定义为排便频率降低≥30%和/或腹痛评分降低≥30%且两者均不差于基线。
- 1年临床缓解定义为CDAI<150。
- 1年内镜缓解定义为SES-CD<3。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is unclear whether improvement in patient-reported outcomes (PROs) relative to baseline symptom burden in Crohn's disease (CD) is associated with subsequent endoscopic remission. AIM: To evaluate the relationship between dominant PRO resolution post-induction and achievement of clinical and endoscopic remission. METHODS: This post-hoc analysis of clinical trial data from 251 participants evaluated the relationship between the resolution of the dominant PRO (most severely elevated baseline PRO) or clinical response (CDAI ≥100 reduction) after induction therapy with biologics (post-induction) and 1-year clinical remission (CDAI <150) and/or endoscopic remission (SES-CD <3). Multivariate logistic regression models evaluated the relationship between post-induction-dominant PRO resolution and 1-year outcomes adjusted for confounders. RESULTS: Participants with dominant PRO resolution post-induction had higher odds of combined endoscopic and clinical remission compared to those without resolution (aOR: 1.94 [95% CI: 1.01-3.74], P = 0.047). Combining dominant PRO resolution with post-induction endoscopic response (SES-CD ≥50% reduction) was associated with higher odds of 1-year endoscopic and clinical remission (aOR: 6.89 [95% CI: 1.65-28.72], P = 0.008). Clinical and PRO2 response (≥30% decrease in stool frequency and/or ≥30% decrease in abdominal pain score and both not worse than baseline) at post-induction did not predict these outcomes. No significant differences were observed with 1-year endoscopic remission for post-induction-dominant PRO resolution, clinical or PRO2 response. CONCLUSIONS: Post-induction resolution of dominant PRO, but not clinical or PRO2 response, was strongly associated with 1-year endoscopic and clinical remission. Resolution of dominant baseline PRO after induction therapy may be informative for 1-year outcomes. Further validation is required.
引用
- Wong ECL, Dulai PS, Marshall JK, et al. Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn's disease. Aliment Pharmacol Ther. 2022. PMID: 35166396. doi:10.1111/apt.16805
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。